Advertisement
Screener

Akari Therapeutics, Plc (AKTX) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Akari Therapeutics, Plc Stock-Based Compensation

Akari Therapeutics, Plc (AKTX) reported Stock-Based Compensation of $1.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-13

  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $711.00K, a 1.11% decline year-over-year.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $305.00K, a 69.95% decline year-over-year.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $471.00K, a 62.50% decline year-over-year.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $685.00K, a 176.21% increase year-over-year.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for fiscal 2025 was $2.89M, a 28.73% increase from fiscal 2024.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for fiscal 2024 was $2.25M, a 95.22% increase from fiscal 2023.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for fiscal 2023 was $1.15M.
  • Akari Therapeutics, Plc share-based payment arrangement, noncash expense for fiscal 2013 was $94.00K, a 81.71% decline from fiscal 2012.
Period endShare-based Payment Arrangement, Noncash Expense 1 monthShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 3 month as first filedShare-based Payment Arrangement, Noncash Expense 4 monthShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 6 month as first filedShare-based Payment Arrangement, Noncash Expense 8 monthShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 12 month as first filedShare-based Payment Arrangement, Noncash Expense 15 monthShare-based Payment Arrangement, Noncash Expense 99 monthShare-based Payment Arrangement, Noncash Expense 111 month
2026-06-30$711.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$1.02M
10-Q · filed 2026-08-13
$1.49M
derived: sum of 3 quarters · filed 2026-08-13
$2.17M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$305.00K
10-Q · filed 2026-05-19
$776.00K
derived: sum of 2 quarters · filed 2026-05-19
$1.46M
derived: sum of 3 quarters · filed 2026-05-19
$2.18M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$471.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$1.16M
derived: sum of 2 quarters · filed 2026-03-30
$1.88M
derived: sum of 3 quarters · filed 2026-08-13
$2.89M
10-K · filed 2026-03-30
2025-09-30$685.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$1.40M
derived: sum of 2 quarters · filed 2026-08-13
$2.42M
10-Q · filed 2025-11-13
$3.67M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$719.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$1.73M
10-Q · filed 2026-08-13
$2.99M
derived: sum of 3 quarters · filed 2026-08-13
$3.24M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$1.01M
10-Q · filed 2026-05-19
$2.27M
derived: sum of 2 quarters · filed 2026-05-19
$2.52M
derived: sum of 3 quarters · filed 2026-05-19
$2.96M
derived: sum of 4 quarters · filed 2026-05-19
2024-12-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$1.50M
derived: sum of 2 quarters · filed 2026-03-30
$1.95M
derived: sum of 3 quarters · filed 2026-03-30
$2.25M
10-K · filed 2026-03-30
2024-09-30$248.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$693.00K
derived: sum of 2 quarters · filed 2025-11-13
$989.00K
10-Q · filed 2025-11-13
$1.29M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30$445.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$741.00K
10-Q · filed 2025-08-13
$1.04M
derived: sum of 3 quarters · filed 2025-08-13
$1.59M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31$296.00K
10-Q · filed 2025-05-14
$600.00K
derived: sum of 2 quarters · filed 2025-05-14
$1.15M
derived: sum of 3 quarters · filed 2025-05-14
$1.18M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$304.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
$851.56K
derived: sum of 2 quarters · filed 2025-04-15
$885.00K
derived: sum of 3 quarters · filed 2025-04-15
$1.15M
10-K · filed 2025-04-15
2023-09-30$547.56K
derived: 10-Q 9 month − 8-K 6 month · filed 2024-11-19
$581.00K
derived: sum of 2 quarters · filed 2024-11-19
$846.00K
10-Q · filed 2024-11-19
2023-06-30$33.44K
derived: 8-K 6 month − 10-Q 3 month · filed 2024-09-06
$298.44K
8-K · filed 2024-09-06
$541.53K
6-K · filed 2023-09-29
2023-03-31$265.00K
10-Q · filed 2024-05-15
2022-12-31$560.06K
8-K · filed 2024-09-06
$735.11K
20-F · filed 2023-05-01
2022-06-30$221.69K
6-K · filed 2023-09-29
2021-12-31$314.65K
20-F · filed 2023-05-01
2021-06-30$166.99K
6-K · filed 2022-09-27
2020-12-31$80.58K
derived: 20-F 12 month − 20-F 9 month · filed 2023-05-01
$161.69K
derived: sum of 2 quarters · filed 2023-05-01
$225.02K
derived: sum of 3 quarters · filed 2023-05-01
$325.52K
20-F · filed 2023-05-01
2020-09-30$81.11K
derived: 20-F 9 month − 6-K 6 month · filed 2021-04-21
$144.44K
derived: sum of 2 quarters · filed 2021-09-22
$244.94K
20-F · filed 2021-04-21
$350.88K
derived: sum of 4 quarters · filed 2022-05-16
2020-06-30$63.33K
derived: 6-K 6 month − 20-F 3 month · filed 2021-09-22
$163.83K
6-K · filed 2021-09-22
$269.77K
derived: sum of 3 quarters · filed 2022-05-16
$407.16K
derived: sum of 4 quarters · filed 2022-05-16
2020-03-31$100.50K
20-F · filed 2021-04-21
$206.44K
derived: sum of 2 quarters · filed 2022-05-16
$343.83K
derived: sum of 3 quarters · filed 2022-05-16
$753.45K
derived: sum of 4 quarters · filed 2022-05-16
2019-12-31$105.94K
derived: 20-F 12 month − 20-F 9 month · filed 2022-05-16
$243.33K
derived: sum of 2 quarters · filed 2022-05-16
$652.95K
derived: sum of 3 quarters · filed 2022-05-16
$1.05M
20-F · filed 2022-05-16
2019-09-30$137.38K
derived: 20-F 9 month − 20-F 6 month · filed 2021-04-21
$547.01K
derived: sum of 2 quarters · filed 2021-04-21
$941.45K
20-F · filed 2021-04-21
2019-06-30$409.62K
derived: 20-F 6 month − 20-F 3 month · filed 2021-04-21
$804.06K
20-F · filed 2021-04-21
2019-03-31$394.44K
20-F · filed 2021-04-21
2018-12-31$1.65M
20-F · filed 2021-04-21
2018-06-30$827.94K
6-K · filed 2019-08-29
2017-12-31$2.73M
20-F · filed 2020-03-31
2017-06-30$1.75M
6-K · filed 2018-09-27
2016-12-31$3.93M
20-F · filed 2019-04-23
2016-06-30$805.41K
derived: 6-K 6 month − 10-Q 3 month · filed 2017-08-10
$1.62M
6-K · filed 2017-08-10
$2.59M
derived: sum of 3 quarters · filed 2018-07-18
$2.66M
derived: sum of 4 quarters · filed 2018-07-18
2016-03-31$816.80K
10-Q · filed 2016-05-12
$1.78M
derived: sum of 2 quarters · filed 2018-07-18
$1.86M
derived: sum of 3 quarters · filed 2018-07-18
$1.86M
derived: sum of 4 quarters · filed 2018-07-18
2015-12-31$963.80K
derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18
$1.04M
derived: sum of 2 quarters · filed 2018-07-18
$1.04M
derived: sum of 3 quarters · filed 2018-07-18
$1.04M
20-F · filed 2018-07-18
2015-09-30$76.06K
derived: 10-Q 9 month − 6-K 6 month · filed 2015-11-23
$76.06K
derived: sum of 2 quarters · filed 2017-04-14
$76.06K
10-Q · filed 2015-11-23
$76.06K
derived: sum of 4 quarters · filed 2017-04-14
2015-06-30$0.00
derived: 6-K 6 month − 10-Q 3 month · filed 2017-04-14
$0.00
6-K · filed 2017-04-14
$108.00K
10-Q · filed 2015-08-12
$0.00
derived: sum of 3 quarters · filed 2017-04-14
-$351.00K
derived: sum of 4 quarters · filed 2017-04-14
2015-03-31$0.00
10-Q · filed 2016-05-12
$59.00K
10-Q · filed 2015-05-12
$0.00
derived: sum of 2 quarters · filed 2017-03-31
-$351.00K
derived: sum of 3 quarters · filed 2017-03-31
-$195.00K
derived: sum of 4 quarters · filed 2017-03-31
2014-12-31$0.00
derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31
-$351.00K
derived: sum of 2 quarters · filed 2017-03-31
-$195.00K
derived: sum of 3 quarters · filed 2017-03-31
$0.00
20-F · filed 2017-03-31
$468.00K
10-K · filed 2015-02-11
2014-09-30-$351.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-23
-$195.00K
derived: sum of 2 quarters · filed 2015-11-23
$0.00
10-Q · filed 2015-11-23
2014-08-30$2.00K
10-K · filed 2015-02-11
2014-06-30$156.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12
$351.00K
10-Q · filed 2015-08-12
2014-03-31$195.00K
10-Q · filed 2015-05-12
2013-12-31$94.00K
10-K · filed 2015-02-11
$1.62M
20-F · filed 2014-03-24
2012-12-31$514.00K
10-K · filed 2015-02-11
$1.53M
20-F/A · filed 2013-04-19
2012-08-31$120.00K
10-K · filed 2015-02-11
2012-06-30$2.00K
20-F · filed 2014-03-24
2011-12-31$140.00K
20-F · filed 2014-03-24
2010-12-31$0.00
20-F/A · filed 2013-04-19
2009-12-31$70.00K
20-F/A · filed 2013-04-19
2008-12-31$168.00K
20-F/A · filed 2013-04-19
2007-12-31$448.00K
20-F/A · filed 2013-04-19
2006-12-31$69.00K
20-F/A · filed 2013-04-19
2005-12-31$119.00K
20-F/A · filed 2013-04-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
ELI LILLY & Co (LLY)United States$1,113.804B42.28
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
AbbVie Inc. (ABBV)United States$468.180B70.37
Merck & Co., Inc. (MRK)United States$365.215B99.96
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94